

Pharmazie

Ronald Niebecker


**Population Pharmacokinetic
Modelling and Simulation of
Monoclonal Antibodies Including
the Impact of Immunogenicity and
Importance of Study and Analysis
Design Factors**

**SHAKER
VERLAG**

Berichte aus der Pharmazie

Ronald Niebecker

**Population Pharmacokinetic Modelling and
Simulation of Monoclonal Antibodies Including
the Impact of Immunogenicity and Importance
of Study and Analysis Design Factors**



D 188 (Diss. Freie Universität Berlin)

Shaker Verlag
Aachen 2014

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available in the Internet at <http://dnb.d-nb.de>.

Zugl.: Berlin, Freie Univ., Diss., 2013

Copyright Shaker Verlag 2014

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers.

Printed in Germany.

ISBN 978-3-8440-2650-4

ISSN 0945-0939

Shaker Verlag GmbH • P.O. BOX 101818 • D-52018 Aachen

Phone: 0049/2407/9596-0 • Telefax: 0049/2407/9596-9

Internet: www.shaker.de • e-mail: info@shaker.de

Population Pharmacokinetic Modelling and Simulation of Monoclonal Antibodies Including the Impact of Immunogenicity and Importance of Study and Analysis Design Factors

Dissertation zur Erlangung des akademischen Grades des
Doktors der Naturwissenschaften (Dr. rer. nat.)

eingereicht im Fachbereich Biologie, Chemie, Pharmazie
der Freien Universität Berlin

vorgelegt von
Ronald Niebecker
aus Rostock
2013

Diese Arbeit wurde von 2009 bis 2013 unter der Leitung von Prof. Dr. Charlotte Kloft am Institut für Pharmazie der Martin-Luther-Universität Halle-Wittenberg (bis Mai 2011) und der Freien Universität Berlin (ab Mai 2011) angefertigt.

1. Gutachter: Prof. Dr. Charlotte Kloft
2. Gutachter: Prof. Dr. Bernd Meibohm

Disputation am 29. Oktober 2013

Für meine Familie

Abbreviations and symbols

Abbreviation	Definition
AAA	Anti-adalimumab antibodies
AAPS	American Association of Pharmaceutical Scientists
AAR	Anti-antibody response
ABW	Adjusted body weight
ADA(s)	Anti-drug antibody/ies
ADME	Absorption, distribution, metabolism, excretion
ADR	Adverse drug reaction
ADVAN	PREDPP subroutine for general nonlinear models
AIC	Akaike information criterion
ATI	Antibodies to infliximab
AU	Arbitrary units
AUC(s)	Area(s) under the curve
BMI	Body mass index
BQL	Below lower limit of quantification
BSA	Body surface area
CD	cluster of differentiation
CDD	Case deletion diagnostics
CDR	Complementarity determining regions
CI	Confidence interval
CID	Chronic inflammatory diseases
CL_ADA	Clearance caused by ADAs
CLC	Central linear clearance (model developed in project I)
CLL	Linear clearance
CLNL	Intrinsic clearance, computed as VMAX/KM
$C_{\max}$	Maximum plasma concentration
$C_{\min}$	Minimum (trough) plasma concentration
%CV	% coefficient of variation
CWRES	Conditional weighted residuals
df	Degree(s) of freedom
DPP4	Dipeptidyl peptidase 4 (gene family)

continued...

Abbreviation	Definition
EBE	Empirical Bayes estimates
ECL	Electrochemiluminescence assay
ECM	Extracellular matrix
EDA	Exploratory data analysis
EGA	Exploratory graphical analysis
ELISA	Enzyme-linked immunosorbent assay
EMA	European Medicines Agency
EPAR	European Public Assessment Report
ES	Effect size
Fab	Fragment antigen-binding
FAP	Fibroblast activation protein
Fc	Fragment crystallisable
Fc γ R	Fc gamma receptor
FcRn	Neonatal Fc receptor
FDA	United States Food and Drug Administration
FFM	Fat-free mass
FO	First-order estimation method
FOCE	First-order conditional estimation method
FOCE+I	FOCE estimation method with interaction
GLS	Generalised least squares
HACA	Human anti-chimeric antibodies
HAFA	Human anti-fusion protein antibodies
HAGR	Human anti-globulin response
HAHA	Human anti-human antibodies
HAMA	Human anti-murine antibodies
HT	Height
IBW	Ideal body weight
Ig	Immunoglobulin
IIV	Interindividual variability
IM	Intramuscular
IOV	Interoccasion variability
ISV	Interstudy variability
IV	Intravenous
KM	Michaelis-Menten constant
LAP	Laplacian estimation method

continued...

Abbreviation	Definition
LAP+I	LAP estimation method with interaction
LBM	Lean body mass
LL	Log likelihood
LLOQ	Lower limit of quantification
LLP	Log likelihood profiling
LOCF	Last observation carried forward
LRT	Likelihood ratio test
MAPE	Median absolute percent estimation error
ML	Maximum likelihood
MPE	Median percent estimation error
NCA	Non-compartmental analysis
NLME	Nonlinear mixed-effect(s)
NM-TRAN	NONMEM translator (part of NONMEM)
NONMEM	Nonlinear mixed-effect modelling software
OBJ _{ELS}	Extended least squares objective function
OFV	Objective function value
PBPK	Physiologically-based pharmacokinetics
PLC	Peripheral linear clearance (model developed in project I)
PNWT	Predicted normal weight
POCA	Power coefficient for nonlinear CL_ADA model (project III)
PPC	Posterior predictive check
PRED	Prediction subroutine (part of NONMEM)
PREDPP	Prediction for population pharmacokinetics (part of NONMEM)
PsN	Perl-speaks-NONMEM
Q	Intercompartmental clearance
R	Software for various data analyses
RIA	Radioimmunoassay
RIPA	Radioimmunoprecipitation assay
RME	Receptor-mediated endocytosis
RSE	Relative standard error
RSV	Residual variability
RU	Response units
SACA	Saturation parameter for nonlinear CL_ADA model (project III)
SC	Subcutaneous
SIGDIG	Number of significant digits

continued...

Abbreviation	Definition
SPR	Surface plasmon resonance
STS	Standard two-stage method
TALD	Time after last dose
$t_{\max}$	Time of $C_{\max}$
TMDD	Target-mediated drug disposition
TNF- α	Tumour necrosis factor alpha
TOL	Tolerance
ULOQ	Upper limit of quantification
ΔV_{ADA}	Increased distributional space caused by ADAs
VMAX	Maximum elimination rate achievable (Michaelis-Menten parameter)
VPC	Visual predictive check
Vss	Volume of distribution at steady-state
V _x	Volume of distribution of xth compartment
WRES	Weighted residuals
WT	Weight
Xpose	Graphic library for R

end

Symbol	Definition
$f()$	Function relating observations to model predictions
$g()$	Function relating model parameters to population parameters and covariates
P_{ki}	Individual parameter estimate for k th parameter and i th individual
$var(y_i)$	Variance-covariance matrix for y_i
x_{ij}	Model input for the i th individual at the j th time point, including all aspects of study design
y_i	Vector of the observations of the dependent variable for the i th individual
y_{ij}	Observations for the i th individual at the j th time point
$\hat{y}_i$	Vector of model predictions/expectations
z_i	Covariates observed in the i th individual
ϵ	Random-effects parameter, residual variability
ϵ_{ij}	Vector of residuals between observed values and model-predicted values, for the i th individual in the j th observation
η	Random-effects parameter, interindividual variability
η_i	Vector of interindividual random-effects in i th individual
Θ	Vector of typical population parameter estimates
θ	Typical population parameter estimate
κ	Random-effects parameter, interoccasion variability
κ_{im}	Vector of interoccasion random-effects in the i th individual at the m th occasion
π^2	Variance for κ
ρ	Correlation coefficient
Σ	Variance-covariance matrix for ϵs
σ^2	Variance for σ
$\sigma_i \sigma_j$	Covariance between two σs
ϕ_i	Model parameters of the i th individual
Ω	Variance-covariance matrix for ηs
ω^2	Variance for η
$\omega_i \omega_j$	Covariance between between two ηs

Contents

Abbreviations and symbols

vii

1 Introduction

1

1.1	Pharmacometrics – modelling and simulation	1
1.1.1	Overview and background	1
1.1.2	Population analysis using the nonlinear mixed-effects approach	4
1.1.3	Simulation-based analysis	5
1.2	Monoclonal Antibodies	5
1.2.1	Monoclonal antibody structure and history	5
1.2.2	Pharmacokinetics of monoclonal antibodies	6
1.2.2.1	Absorption	6
1.2.2.2	Distribution	7
1.2.2.3	Metabolism and excretion	8
1.2.2.4	Population pharmacokinetics of monoclonal antibodies	8
1.2.3	Pharmacodynamics of monoclonal antibodies	9
1.2.4	Safety of monoclonal antibodies	10
1.2.5	Sibrotuzumab	10
1.3	Immunogenicity	12
1.3.1	Causes of immunogenicity	12
1.3.2	Anti-drug antibody terminology and classification	12
1.3.3	Factors influencing the immune response	13
1.3.4	Incidence of anti-drug antibody development	14
1.3.5	Potential impact of anti-drug antibodies	14
1.3.6	Management of immunogenicity	15
1.3.7	Immunogenicity bioanalytics	17
1.3.7.1	Causes of challenges in immunogenicity bioanalytics	17
1.3.7.2	Risk-based approaches to immunogenicity assessment	18
1.3.7.3	Recommendations for assay development and validation	19
1.3.7.4	Overview of methods in immunogenicity bioanalytics	19
1.3.8	Immunogenicity in pharmacometrics	21
1.4	Design factors of clinical trials and evaluation for identifiability of pharmacokinetic parameters	22
1.4.1	Study and analysis design factors	22
1.4.2	Approaches to investigate importance of study design factors	23
1.5	Objectives	23

2	Methods and Studies	25
2.1	Population analysis using the NLME approach	25
2.1.1	Nonlinear mixed-effects modelling	25
2.1.1.1	NONMEM	25
2.1.1.2	Model components	25
2.1.1.3	Estimation methods and further technical specifications	28
2.1.2	Model development	31
2.1.2.1	Structural submodel	31
2.1.2.2	Stochastic submodel	31
2.1.2.3	Covariate submodel	34
2.1.3	Model selection	39
2.1.4	Model evaluation	40
2.1.4.1	External evaluation	40
2.1.4.2	Internal evaluation	41
2.2	Simulations	42
2.2.1	Deterministic simulations	43
2.2.2	Stochastic simulations	43
2.2.3	Simulation-based analyses	43
2.3	Experimental design/clinical studies	44
2.3.1	Study objectives	44
2.3.2	Study design	44
2.3.2.1	Study population	44
2.3.2.2	Study treatment	46
2.3.2.3	Sampling of sibrotuzumab	46
2.3.2.4	Sampling for immune response	46
2.3.3	Bioanalytical methods	46
2.3.3.1	Sibrotuzumab bioanalytics	47
2.3.3.2	Immune response analytics	48
2.4	Data preparation	49
2.4.1	Data sources and dataset modification	49
2.4.2	Data checkout and exploratory data analysis	49
2.4.3	Exploratory graphical analysis	49
2.4.4	Missing data	49
2.5	Modelling and simulation strategies	50
2.5.1	Project I: Sibrotuzumab population pharmacokinetics prior to immune response	50
2.5.1.1	Objectives and initial situation	50
2.5.1.2	Investigations concerning the structural submodel	51
2.5.1.3	Investigations concerning the stochastic submodel	52
2.5.1.4	Investigations concerning the covariate submodel	52
2.5.1.5	Model evaluation including simulations	53
2.5.2	Project II: Modelling of an immune response surrogate	54
2.5.2.1	Objectives	54
2.5.2.2	Investigations concerning the different submodels	54
2.5.2.3	Model evaluation including simulations	55

2.5.3	Project III: Modelling of the anti-drug antibody influence on the population pharmacokinetics of sibrotuzumab	55
2.5.3.1	Objectives and initial considerations	55
2.5.3.2	Investigations concerning the different submodels	56
2.5.3.3	Model evaluation including simulations	57
2.5.4	Project IV: Simulation-based analysis concerning the importance of design factors for parameter identifiability	58
2.5.4.1	Objectives	58
2.5.4.2	Technical implementation and workflow evaluation	58
2.5.4.3	Workflow application	61
2.6	Statistics	64
2.6.1	Descriptive statistics	64
2.6.2	Inferential statistics	64
2.7	Software	65
3	Results	67
3.1	Results relevant to projects I–III	67
3.1.1	Patient characteristics	67
3.1.2	Drug administrations	68
3.1.3	Immunogenicity	68
3.1.4	Therapeutic monoclonal antibody measurements	69
3.1.5	Anti-drug antibody measurements	71
3.1.6	Datasets for analysis	71
3.2	Project I: Sibrotuzumab population pharmacokinetics	72
3.2.1	Observations: sibrotuzumab concentration-time profiles	72
3.2.2	Model development	72
3.2.2.1	Structural submodel	72
3.2.2.2	Stochastic submodel	74
3.2.2.3	Covariate submodel	75
3.2.3	Final models	81
3.2.4	Model evaluation	84
3.2.4.1	Basic internal model evaluation	84
3.2.4.2	Case-deletion diagnostics	84
3.2.4.3	Robustness of convergence	87
3.2.4.4	Bootstrap analysis	87
3.2.4.5	Comparison of confidence intervals	89
3.2.4.6	Visual predictive check analysis	93
3.2.4.7	Summary of model evaluation results	93
3.2.5	Simulations	97
3.2.5.1	Comparison of CLC model and PLC model	97
3.2.5.2	Comparison of CLC model with the previous model for sibrotuzumab pharmacokinetics	98
3.2.5.3	Simulations concerning the impact of body size	100
3.3	Project II: Immune response surrogate modelling	106
3.3.1	Observations: surface plasmon resonance assay signal-time profiles	106

3.3.2	Model development	106
3.3.2.1	Structural submodel	106
3.3.2.2	Stochastical submodel	109
3.3.2.3	Covariate submodel	109
3.3.3	Final models	109
3.3.4	Model evaluation including simulations	112
3.3.4.1	Basic internal model evaluation	112
3.3.4.2	Simulations	116
3.3.4.3	Advanced internal model evaluation	117
3.4	Project III: ADA influence on sibtrotuzumab pharmacokinetics	120
3.4.1	Observations	120
3.4.2	Model development for dataset I	123
3.4.2.1	Application of the unaltered CLC model	124
3.4.2.2	Structural submodel	128
3.4.2.3	Stochastical submodel	128
3.4.2.4	Covariate submodel	129
3.4.3	Final models for dataset I	130
3.4.4	Model development and final models for dataset II	132
3.4.5	Model evaluation	134
3.4.5.1	Basic internal model evaluation	134
3.4.5.2	Advanced internal model evaluation	137
3.4.6	Simulations	141
3.5	Project IV: Design factors/Simulation-based analysis	144
3.5.1	Workflow implementation	144
3.5.2	Workflow evaluation	146
3.5.3	Workflow application	146
3.5.3.1	Simulation study I	147
3.5.3.2	Simulation study II	148
4	Discussion	157
4.1	Population pharmacokinetic analysis of monoclonal antibodies	157
4.1.1	Data basis	157
4.1.2	Population pharmacokinetic model and parameters	158
4.1.2.1	Structural submodel	158
4.1.2.2	Stochastical submodel	165
4.1.2.3	Covariate submodel	168
4.1.3	Impact of estimation method	174
4.1.4	Final assessment	175
4.2	Immunogenicity in monoclonal antibody pharmacokinetics	176
4.2.1	Clinical findings concerning immunogenicity	176
4.2.2	Modelling of an immune response surrogate	177
4.2.2.1	Data basis and modelling approach	177
4.2.2.2	Structural submodel	179
4.2.2.3	Covariate submodel	180
4.2.2.4	Short summary	180